Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Purpose of review This is an update of data regarding changes in blood pressure using sodium-glucose co-transporter 2 inhibitors (SGLT2i) for the treatment of diabetes. The mechanism of blood pressure lowering by SGLT2i was thought to be due to their osmotic diuretic effects. New data, however, has emerged from meta-analyses and studies of people with impaired kidney function demonstrating similar or greater magnitudes of blood pressure reduction in the absence of significant glycosuria. Potential additional mechanisms are proposed and reviewed.Recent findings Two separate meta-analyses in over 10,000 participants combined demonstrate an average of 4/2 mmHg reduction in blood pressure by SGLT2i. This includes consistency between measurements of in-office and ambulatory blood pressure monitoring. This reduction extends to decreases in nocturnal blood pressure of 2.6 mmHg systolic pressure. These reductions in blood pressure by SGLT2i are also present when added to ongoing treatment with ACE inhibitors or ARBs. In one study, dapagliflozin, when added to a regimen of a renin-angiotensin-aldosterone system (RAAS) antagonist and a diuretic, further lowered in-office systolic pressure by 2.4 mmHg. In contrast, when prescribed to those on a RAAS antagonist plus a calcium channel blocker or RAAS antagonist plus a beta blocker, systolic pressure decreased 5.4 mmHg. Lastly, post hoc analyses of major cardiovascular outcome trials across the spectrum of estimated glomerular filtration rates from 30 to 80 ml/min/1.73 m2 demonstrated similar magnitudes of BP reduction in spite of far less reduction in glucosuria among those with advanced kidney disease. Moreover, recent data implicate the potential for increased ketones associated with SGLT2i contributing to blood pressure lowering in advanced-stage kidney disease. SGLT2i are well established to lower blood pressure. Their mechanism appears to be multifactorial and has a hemodynamic as well as metabolic component contributing to this reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While the glycosuric effect of SGLT2 inhibition diminishes substantially as kidney function declines, effects on systolic BP appear preserved across the spectrum of eGFR studied to date, including down to an eGFR <30 mL/min/1.73m 2 .[25][26][27]”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [25]
Citations
Cites
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Yale, J. ‐., Bakris, G., Cariou, B., Yue, D., David‐Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12090 · Cited by 487
Self-citationCherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Cited by
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationHypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
Burnier, M., & Damianaki, A. (2023) · Circulation Research · doi:10.1161/circresaha.122.321762 · Cited by 400
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167
Bakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10140620 · Cited by 142
Self-citation
Metadata
- Authors
- Sternlicht, H., & Bakris, G. L.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Bakris, George L.
- Venue
- Current Hypertension Reports
- Published
- 2019-02
- Volume
- 21
- Issue
- 2
- Pages
- 12-12
- ISSN
- 1522-6417 (ISSN-L)
- 1534-3111
- OpenAlex
- W2913564090
- Cited by
- 60
- References
- 31
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 9 · 2022: 6 · 2021: 14 · 2020: 18 · 2019: 5
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Hypertension Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, blood pressure reduction, osmotic diuresis, dapagliflozin, impaired kidney function, advanced chronic kidney disease, ketones, glycosuria, nocturnal blood pressure, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Blood Pressure, Diuresis, Glucose, Humans, Hypertension, Sodium, Blood Pressure Monitoring, Ambulatory, Symporters
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. https://app.cochat.ai/papers/10.1007/s11906-019-0920-4
- The paper
- Sternlicht, H., & Bakris, G. L. (2019). Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Current Hypertension Reports. https://doi.org/10.1007/s11906-019-0920-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.